InvestorsKeyhole Insider Activity

Biogen CEO buys more than $250k in stock

Michel Vounatsos, the CEO of Biogen (BIIB), bought 780 shares of the company’s common stock on Dec. 29. At $320.55 per share, Vounatsos paid a total of $250,029 for the new shares.

Already a member?

Login to see your Insider Activity Trade Idea.

Not yet a member?

You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.

Become A Member

BIIB
About Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Tysabri and Tecfidera. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

  • Last Price:
    $225.76
  • Previous Close:
    $223.21
  • Change:
    $2.55 (1.14%)
  • Open:
    $222.50
  • Volume:
    2,545,625
  • Average Volume (100 Day):
    1,513,480
  • Market Capitalization:
    $41.6 B
  • Day's Range:
    $221.84 - $226.38
  • Dividend Yield:
    0.00%
  • 52-week Range:
    $344 - $215.77
  • P-E:
    8.20
  • EPS:
    $26.90
  • Earnings Date:
    10/22/19
  • Ex Dividend Date:
    N/A
  • Sector:
    Healthcare
  • Industry:
    Drug Manufacturers - Major
  • Analyst Average Recommendation:
    Hold

Download this step-by-step guide on placing InvestorsKeyhole Daily Trade Alerts.

How to place a credit spread

How to place a vertical debit spread

|

You May Also Like